As an increased incidence of thrombotic vascular events (TVEs) has been observed in cancer patients receiving erythropoiesis-stimulating agents (see section 4.8), this risk should be carefully weighed against the benefit to be derived from treatment (with epoetin alfa) particularly in cancer patients with an increased risk of thrombotic vascular events, such as obesity and patients with a prior history of TVEs (e. g. deep vein thrombosis or pulmonary embolism).
Tätä riskiä on punnittava huolellisesti (epoetiini alfa -) hoidosta saataviin hyötyihin nähden erityisesti niillä syöpäpotilailla, joilla verisuonitapahtumien riski on lisääntynyt, kuten ylipainoisilla potilailla ja potilailla, joilla on aiemmin ollut verisuonitapahtumia (esim. syvä laskimotukos tai keuhkoembolia).